Efficacy of nivolumab (Nivo) as 2+line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients: Interim results of observational prospective study.

被引：1
|
作者：
Laktionov, Konstantin K.
Arzumanyan, Alla L.
Bolotina, Larisa
Breder, Valeriy Vladimirovich
Buevich, Natalia N.
Danilova, Anastasia
Filippova, Elena A.
Kornietskaya, Anna
Kramchaninov, Mikhail M.
Kushniruk, Eugenia K.
Latipova, Dilorom H.
Moiseenko, Fedor Vladimirovich
Nikitina, Tatiana P.
Orlov, Sergey V.
Orlova, Rashida
Protsenko, Svetlana A.
Sarantseva, Ksenia A.
Stroyakovskiy, Daniil L.
Zinkovskaya, Anna V.
机构：
[1] N N Blokhin Russian Canc Res Ctr, Moscow, Russia
[2] Minist Hlth, Hertsen Moscow Oncol Res Inst, Natl Med Res Radiol Ctr, Moscow, Russia
[3] Natl Med Res Ctr Oncol n N Blokhin, Moscow, Russia
[4] N N Petrov Res Inst Oncol, St Petersburg, Russia
[5] Moscow Dept Hlth, Moscow City Oncol Hosp 62, Moscow, Russia
[6] Pavlov St Petersburg State Med Univ, R M Gorbacheva Mem Inst Children Hematol & Transp, St Petersburg, Russia
[7] St Petersburg Clin Res Ctr Specialized Types Med, St Petersburg, Russia
[8] City Clin Oncol Dispensary, St Petersburg, Russia
[9] Multinat Ctr Qual Life Res, St Petersburg, Russia
[10] St Petersburg State Univ, St Petersburg, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21126
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Prospective data from QoL surveys in patients receiving chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Kasymjanova, G
    Lajeunesse, L
    Dajczman, E
    Kreisman, H
    Small, D
    LUNG CANCER, 2005, 49 : S337 - S337
  • [22] Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study
    Takayama, Koichi
    Atagi, Shinji
    Imamura, Fumio
    Tanaka, Hiroshi
    Minato, Koichi
    Harada, Toshiyuki
    Katakami, Nobuyuki
    Yokoyama, Takuma
    Yoshimori, Kozo
    Takiguchi, Yuichi
    Hataji, Osamu
    Takeda, Yuichiro
    Aoe, Keisuke
    Kim, Young Hak
    Yokota, Soichiro
    Tabeta, Hiroshi
    Tomii, Keisuke
    Ohashi, Yasuo
    Eguchi, Kenji
    Watanabe, Koshiro
    SUPPORTIVE CARE IN CANCER, 2016, 24 (08) : 3473 - 3480
  • [23] Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer
    Goto, Yasushi
    Yoh, Kiyotaka
    Kato, Terufumi
    Hosomi, Yukio
    Usui, Kazuhiro
    Fukui, Tomoya
    Hirano, Katsuya
    Tanaka, Hiroshi
    Taguri, Masataka
    Kunitoh, Hideo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (02) : 153 - 160
  • [24] Prognostic factors for survival of non-small cell lung cancer (NSCLC). Results of a prospective multicenter study.
    Fuentes, R
    Bover, I
    Canals, E
    Rifa, J
    Moreno, V
    Barreiro, E
    Beltran, M
    Viladiu, P
    BRITISH JOURNAL OF CANCER, 1996, 74 : PO23 - PO23
  • [25] Deterioration of quality of life after surgical treatment of non-small cell lung cancer (NSCLC): an interim analysis
    Pompili, Cecilia
    Franks, Kevin
    Brunelli, Alessandro
    White, John
    Dixon, Sandra
    Callister, Matthew
    Robson, Jonathan
    Velikova, Galina
    QUALITY OF LIFE RESEARCH, 2016, 25 : 159 - 159
  • [26] Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC)
    Costantini, Adrien
    Corny, Jennifer
    Fallet, Vincent
    Renet, Sophie
    Friard, Sylvie
    Chouaid, Christos
    Duchemann, Boris
    Giroux-Leprieur, Etienne
    Taillade, Laurent
    Doucet, Ludovic
    Wislez, Marie
    Tredaniel, Jean
    Cadranel, Jacques
    Jouveshomme, Stephane
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [27] Prolactin as a possible predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)
    Caponnetto, S.
    Mancini, M. L.
    Scagnoli, S.
    Barchiesi, G.
    Mosillo, C.
    Iannantuono, G. M.
    Verkhovskaia, S.
    Magri, V.
    Piesco, G.
    Pomati, G.
    Pellegrino, D.
    Urbano, F.
    Zancla, S.
    Manai, C.
    Cortesi, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] First-line nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC): Results from an interim analysis of the non-interventional FINN study
    Kuon, J. B.
    von der Heyde, E.
    Wilop, S.
    Behringer, D. M.
    Blau, W.
    Huebner, G.
    Flieger, D.
    Forstbauer, H.
    Groschek, M.
    Laack, H-E.
    Mueller-Huesmann, H.
    Schumann, C.
    Waldenberger, D.
    Guetz, S.
    ANNALS OF ONCOLOGY, 2023, 34
  • [29] Efficacy and Tolerability of Nivolumab in Elderly Patients with Advanced Non-Small Cell Lung Cancer
    Yamane, K.
    Takeda, K.
    Yanai, M.
    Tanaka, N.
    Izumi, H.
    Sakamoto, T.
    Yamaguchi, K.
    Yamasaki, A.
    Igishi, T.
    Eiji, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1918 - S1918
  • [30] Number of Treatment Lines Defines Prognosis in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients - a Prospective Observational, Single Center Study
    Mihaylova, Z.
    Petrova, M.
    Petrova, V.
    Petkova, D.
    Fakirova, A.
    Babakolova, R.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S615 - S615
12345